Regulators recently approved an updated COVID shot from Novavax. Struggling biotech Novavax (NVAX -0.72%) was a hot buy a few years ago as it was in the midst of developing a vaccine for COVID-19. Ultimately, it did produce an approved vaccine, but it was a bit late and did not end up generating nearly as much in revenue as it could have if it had obtained approval much earlier. And since 2022, a sell-off has ensued, with the stock losing more than 91% of its value. Recently, there's been some renewed excit ...

GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences. H.C. Wainwright 26th Annual Global Investment Conference: Fireside Chat Date: Monday, September 9, 2024 Time: 3:30 – 4:00 p.m. Eastern Time (ET) Location: New York City, New York Moderator: Vernon Bernardino, Managing Director, Senior Healthcare Analyst Novavax partici ...

Novavax (NVAX) announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for individuals aged 12 years and older. Following this nod, Novavax's updated vaccine is the only non-mRNA vaccine option available to people in the United States. Management expects pre-filled syringes of the vaccine to be available across the country. This authorization comes just a week after the agency approved/authorized updated the mRNA-based COVID19 vaccines of ...

Novavax expects pre-filled syringes will be broadly available in thousands of locations across the U.S. Novavax's vaccine is the only protein-based option available in the U.S. for use in individuals aged 12 and older to prevent COVID-19 GAITHERSBURG, Md., Aug. 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) has received Emergency Us ...

A vial labelled "Novavax V COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. The Food and Drug Administration authorized Novavax's updated protein-based Covid vaccine for emergency use in people ages 12 and up on Friday, paving the way for the shot to compete with Pfizer and Moderna's jabs this fall and winter. Novavax's vaccine targets the highly contagious omicron subvariant JN.1, which began circulating widely in the U.S. earlier this year. JN.1 only accounted for 0.2% of cases circu ...

Don't be too quick to jump on the Wall Street bandwagon. It's been a great year for Novavax (NVAX 0.25%). The biotech is up by 150% since January. However, analysts see even more upside for the vaccine maker. The consensus estimate of $20 a share implies a 65% increase over its current stock price, not too shabby for a company that, not too long ago, seemed to be not too far from bankruptcy. Can Novavax maintain its momentum? Let's find out if the biotech can hit the street's price target within the next 12 ...

MCCAIG It has been less than a month since my last Novavax (NASDAQ:NVAX) article, where I discussed partnership with Sanofi (SNY) and updates on their COVID-19 and H5N1 bird flu vaccine programs. Those updates forced me to revise my NVAX strategy to account for upcoming catalysts and the possibility of a sustained rally. Well, that rally turned into a malaise fade over the past few weeks. However, the ticker has experienced a shot of volatility over the past few trading sessions after the company released t ...

Novavax Inc. NASDAQ: NVAX is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Its most significant vaccine, Nuvaxovid, is for COVID-19. The hype surrounding the potential for Nuvaxovid drove Novavax shares as high as $331.68 in February 2021. However, the reality of missteps resulting in being "late to the party" caused shares to crater to $3.53 by February 2024. Shares have since surged as high as $23.86 in June 2024 on a $1.2 billion licensin ...

Novavax (NVAX) posted earnings per share of 99 cents in second-quarter 2024, missing the Zacks Consensus Estimate of $1.82. However, earnings rose 71% year over year. Revenues in the quarter amounted to $415.5 million, also missing the Zacks Consensus Estimate of $453.7 million. The top line declined 2% on a year-over-year basis. Quarter in Detail In the reported quarter, the company recorded $19.9 million in product sales compared with $285.2 million in the year-ago quarter. While this reported figure did ...

Novavax, Inc. (NASDAQ:NVAX) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Erika Schultz - Senior Director of Investor Relations John Jacobs - President and Chief Executive Officer John Trizzino - President and Chief Operating Officer Dr. Bob Walker - Chief Medical Officer and Interim Head of Research and Development Jim Kelly - Chief Financial Officer and Treasurer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank ...